Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Arcus Biosciences Inc shares valued at $153,186 were purchased by Robert C. Goeltz II on Dec 31 ’25. At $23.38 per share, Robert C. Goeltz II acquired 6,552 shares.
Also, Tang Carolyn C. sold 7,658 shares, netting a total of over 167,590 in proceeds. Following the sale of shares at $21.88 each, the insider now holds 131,544 shares.
Before that, Tang Carolyn C. had sold 6,810 shares from its account. In a trade valued at $150,906, the General Counsel traded Arcus Biosciences Inc shares for $22.16 each. Upon closing the transaction, the insider’s holdings decreased to 6,810 shares, worth approximately $2.97 million.
As published in a research note from H.C. Wainwright on February 26, 2025, Arcus Biosciences Inc [RCUS] has been rated up from a Neutral to a Buy and the price target has been revised to $24 from $18. Analysts at H.C. Wainwright started covering the stock with ‘”a Neutral”‘ outlook in a report released in late October. As of October 08, 2024, Wells Fargo has initiated its “an Overweight” rating for RCUS. Earlier on November 18, 2022, BofA Securities initiated its rating. Their recommendation was “a Neutral” for RCUS stock.
Analyzing RCUS Stock Performance
On last trading session, Arcus Biosciences Inc [NYSE: RCUS] rose 2.58% to $23.83. The stock’s lowest price that day was $23.1134, but it reached a high of $24.155 in the same session. During the last five days, there has been a surge of approximately 4.93%. Over the course of the year, Arcus Biosciences Inc shares have jumped approximately 56.06%. Shares of the company reached a 52-week high of $26.40 on 12/09/25 and a 52-week low of $6.50 on 04/07/25.
Support And Resistance Levels for Arcus Biosciences Inc (RCUS)
According to the 24-hour chart, there is a support level at 23.24, which, if violated, would cause prices to drop to 22.66. In the upper region, resistance lies at 24.29. The next price resistance is at 24.74. RSI (Relative Strength Index) is 57.55 on the 14-day chart, showing neutral technical sentiment.
Is Arcus Biosciences Inc subject to short interest?
Stocks of Arcus Biosciences Inc saw a sharp steep in short interest on 2025-12-15 dropping by -2.06 million shares to 7.83 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 9.89 million shares. A decline of -26.28% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.47 of the overall float, the days-to-cover ratio (short ratio) decline to 3.47.
Which companies own the most shares of Arcus Biosciences Inc (RCUS)?
In terms of Arcus Biosciences Inc share price expectations, FactSet research, analysts set an average price target of 31 in the next 12 months, up nearly 33.45% from the previous closing price of $23.23. Analysts anticipate Arcus Biosciences Inc stock to reach 35 by 2026, with the lowest price target being 16. In spite of this, 3 analysts ranked Arcus Biosciences Inc stock as Buy at the end of 2026. On October 11, 2022, Morgan Stanley assigned a price target of “an Overweight” to the stock and initiated coverage with a $40.
